ALXN - Alexion Pharmaceuticals, Inc.

ALXN

$182.50 +0.00 (+0.00%) Last updated: Apr 16, 2026 01:01

52-Week Range

$182.50

$146.00 $182.50 $219.00

Fundamentals Overview

Alexion Pharmaceuticals, Inc. is in the middle of its 52-week range with premium valuation, trading relatively flat today.

Valuation premium

P/E 59.6 P/B 3.43

Profitability

Net margin 9.9%

Risk (Beta)

1.26 — higher vol

Earnings & growth

EPS $3.06 Rev +2.8% Profit +18.7% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 35% confidence Risk: High Volatility — Beta 1.26. Consider smaller position size due to higher beta.

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

N/A

P/E (TTM)

59.58

EPS (TTM)

$3.06

Dividend Yield

N/A

52-Week Range

$146.00 - $219.00

Volume vs Avg

N/A

Beta

1.26

About

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme...

Sector: Healthcare

Headquarters: US

Employees: 3,837

IPO Date: Feb 1996

Website: www.alexion.com

Beta: 1.26 (More volatile than market)

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric	Value
Valuation
P/E (TTM)	59.58
PEG (TTM)	N/A
P/B (TTM)	3.43
P/S (TTM)	N/A
Liquidity & enterprise
Current Ratio (TTM)	3.59
Quick Ratio (TTM)	3.11
Cash Ratio (TTM)	1.82
Profitability
ROE (TTM)	N/A
ROA (TTM)	N/A
Revenue growth (YoY)	N/A
Net margin (TTM)	9.94%
Gross margin (TTM)	90.88%
Operating margin (TTM)	47.12%
Debt to equity (TTM)	N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for ALXN.

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.